| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_006e91eddabe95ad7aa889123d31cb9a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6867
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate |
2019-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8544e0456c012c61900dc22199bdb7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b774453f293a7a895dc873bf092950c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3721bf038e4d8dba9397d356bcfc48a8 |
| publicationDate |
2020-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202003048-A |
| titleOfInvention |
Combination treatment with antibody-drug conjugates and FLT3 inhibitors |
| abstract |
The present invention provides a method of treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of a CD33-targeted antibody-drug conjugate (ADC) and a therapeutically effective amount of quizartinib or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions comprising a therapeutically effective amount of a CD33-targeted ADC and a therapeutically effective amount of quizartinib or a pharmaceutically acceptable salt thereof. |
| priorityDate |
2018-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |